Ideaya Biosciences reports Phase 2 data for MAT2A inhibitor IDE397

Fresh Phase 2 data are adding weight to Ideaya Biosciences’ case for a targeted therapy it believes could be a first-in-class treatment option for certain types of urothelial cancer and lung cancer.

In a study with 18 evaluable patients, Ideaya’s drug helped seven of them shrink their tumors — translating…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks